Abstract:
:We analyzed the expression of CD1d, an antigen-presenting molecule, on peripheral blood leukemic cells of cases of chronic lymphocytic leukemia (CLL) by flow cytometry. We demonstrated variable expression of CD1d on leukemic lymphocytes and an association between high expression of CD1d with shorter time to treatment and overall survival of patients. CD1d was positively associated with CD38 expression, but not with unmutated heavy chain variable (VH) mutational status or adverse cytogenetics of leukemic lymphocytes. Our findings support that CD1d expression is a prognostic marker for CLL.
journal_name
Leuk Lymphomajournal_title
Leukemia & lymphomaauthors
Anastasiadis A,Kotsianidis I,Papadopoulos V,Spanoudakis E,Margaritis D,Christoforidou A,Gouliamtzi S,Tsatalas Cdoi
10.3109/10428194.2013.803222subject
Has Abstractpub_date
2014-02-01 00:00:00pages
320-5issue
2eissn
1042-8194issn
1029-2403journal_volume
55pub_type
杂志文章abstract::We aimed to investigate whether the clinical characteristics, the rate of treatment demand and survival differ between chronic lymphocytic leukemia (CLL) patients <65 years (y) and ≥65 y. Sixty three (46%) patients were <65 y and 74 (54%) were ≥65 y. 28.6% (18/63) of the patients <65 required treatment, while this rat...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2018.1509316
更新日期:2019-03-01 00:00:00
abstract::We describe a patient with acute promyelocytic leukemia (APL) who developed pulmonary embolism (PE) and thrombotic thrombocytopenic purpura (TTP) during remission induction all-trans retinoic acid (ATRA) therapy. A 44-year-old man was diagnosed with APL and was treated with ATRA. On day 14, he developed PE, and on day...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190309178790
更新日期:2003-09-01 00:00:00
abstract::We studied the outcome of 213 patients who received allo-HSCT for hematological malignancies, 121 (57%) from HLA identical siblings, 63 (29%) from 10/10 HLA identical unrelated donors and 29 (14%) from 9/10 HLA mismatched unrelated donors. Engraftment was lower in the 9/10 HLA group (90%) than in the 10/10 HLA group (...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2014.944518
更新日期:2015-04-01 00:00:00
abstract::Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disrupting cell-cell interac...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428194.2018.1457147
更新日期:2018-12-01 00:00:00
abstract::Acute graft versus host disease (aGVHD) was first described by Barnes et al. in 1962, who reported a 'secondary disease' in mice after irradiation and infusion of allogeneic spleen cells. The disease manifested as fatal diarrhea and skin abnormalities. They postulated that aGVHD resulted from introducing immunological...
journal_title:Leukemia & lymphoma
pub_type: 评论,杂志文章
doi:10.1080/10428194.2019.1613545
更新日期:2019-09-01 00:00:00
abstract::The incidence of central nervous system (CNS) involvement and effects of therapy were reviewed in 42 consecutive pediatric patients with acute nonlymphocytic leukemia (ANLL). The morphology of ileukemic cells was considered M1 in 13, M2 in 7, M3 in 5, M4 in 8, and M5 in 9. Two patients with M5 morphology presented wit...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199009042513
更新日期:1990-01-01 00:00:00
abstract::Hematologic malignancies are predominantly treated with chemotherapy or a combination of chemotherapy with monoclonal antibodies. Current treatment regimens often are not satisfactory due to severe side effects and a substantial proportion of relapsed patients. This has prompted the development of better tolerated and...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428190902943077
更新日期:2009-06-01 00:00:00
abstract::Reprimo (RPRM) is a novel tumor suppressor. However, the expression and molecular function of RPRM in pediatric acute myeloid leukemia (AML) is still unknown. We observed hypermethylation of the RPRM promoter in 8/11 leukemia cell lines and in 44.8% (47/105) of pediatric AML samples compared with 6.7% (2/30) of contro...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2015.1011157
更新日期:2015-01-01 00:00:00
abstract::The objective of this work was to determine the safety and efficacy of gemtuzumab ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the following diagnoses/characteristics were treated with 1-3 infusions of gemtuzumab ozogamicin at a dose of 9 mg/m2: (1) relapse of AML < or = 6 mon...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章
doi:10.1080/1042819021000016078
更新日期:2002-10-01 00:00:00
abstract::In order to assess the contribution of FC to the diagnosis of lymph node disorders we retrospectively compared the pathological and the FC diagnosis made in 118 consecutive lymph node biopsies. Pathological diagnosis included non malignant conditions (n = 43), B-cell Non Hodgkin lymphoma (NHL) (n = 30), T-cell NHL (1 ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190310001609906
更新日期:2004-08-01 00:00:00
abstract::Mononuclear phagocytic cells and CD4+ T lymphocytes represent the major targets for infection by HIV-1 in vivo. The most severe pathogenic features associated with HIV-1 infection can be attributed to malfunction or premature death of these cells that are of hematopoietic origin. Patients with acquired immunodeficienc...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428190009058502
更新日期:2000-05-01 00:00:00
abstract::Interleukin-6 (IL-6) has been shown to increase platelet counts in several animal models and to enhance megakaryocytopoiesis in vitro. In order to investigate the possible relationship between IL-6 and thrombocytosis, serum IL-6 levels in patients with platelet counts > or = 6 x 10(5)/microliters were measured using a...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199209054910
更新日期:1992-10-01 00:00:00
abstract::New therapies for relapsing/refractory Hodgkin lymphoma (R/R HL) and R/R systemic anaplastic large-cell lymphoma (sALCL) have emerged. This study captured utility values for R/R HL and sALCL to support economic evaluation. Health state "vignettes" were developed describing states associated with R/R HL and sALCL: trea...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2014.970542
更新日期:2015-06-01 00:00:00
abstract::Myeloperoxidase (MPO) has been shown to catalyze the in vitro degradation of vincristine (VCR). Given that MPO is a lysosomal enzyme that can be released into the circulation by both normal activated and leukemic myeloid cells, we investigated the possibility that sera from patients with acute myeloblastic leukemia (A...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199609052426
更新日期:1996-02-01 00:00:00
abstract::Chronic lymphocytic leukemia (CLL) is at present an incurable disease. All of the drugs used in the treatment of CLL induce apoptosis in the cells, and in vitro responses to glucocorticoid or analogs correlate with in vivo sensitivity to these agents. Since CLL lymphocytes accumulate rather than proliferate, the idea ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199909058447
更新日期:1999-05-01 00:00:00
abstract::Thirteen patients (pts) with highly refractory acute myeloid leukemia (AML) 10 pts with de novo AML and 3 with blast crisis of chronic myeloid leukemia were treated with carboplatin (CP) 150 mg/m2/day through continuous IV infusion for 7 consecutive days. Seven of them received CP at least as third or more line therap...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章
doi:10.3109/10428199409049729
更新日期:1994-10-01 00:00:00
abstract::Phosphatidylglucoside (PtdGlc), a new type of glycolipid, was recently identified. We examined PtdGlc expression in normal blood cells and leukemic cells using an anti-PtdGlc monoclonal antibody, DIM-21. Neutrophils, monocytes, HL-60 cells and a subset of cord blood (CB) CD34(+) cells, but not erythroblasts, expressed...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190902934928
更新日期:2009-07-01 00:00:00
abstract::Treatment of hairy cell leukemia (HCL), a disease first described in 1958, has evolved from splenectomy, which resulted in a normalization of blood counts in about 41% of patients and an improvement in the remaining 59% of patients but with a time to failure of only approximately 19 months, through treatment in the ea...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428194.2011.565094
更新日期:2011-06-01 00:00:00
abstract::The role of malnutrition at diagnosis as a predictor of early mortality in Mexican leukemia children remains controversial. The objective of present study was to investigate whether malnutrition was a predictor of early mortality during the first year of treatment in Mexican acute lymphoblastic leukemia (ALL) children...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,多中心研究
doi:10.1080/10428194.2016.1219904
更新日期:2017-04-01 00:00:00
abstract::Adult T-cell leukemia/lymphoma (ATLL) remains an uncommon disorder outside well-defined risk groups. We describe the case of an Iranian woman, who presented with isolated meningeal relapse of diffuse large-cell lymphoma. The malignant cells coexpressed CD4 and CD8 and HTLV-1 seropositivity was confirmed. Despite combi...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199409073790
更新日期:1994-02-01 00:00:00
abstract::Since etoposide interacts with the nuclear enzyme topoisomerase II, the drug concentrations in the malignant cells during chemotherapy may have clinical correlates. Plasma protein binding of etoposide is extensive (94%) and alterations of the non-proteinbound fraction affect pharmacokinetic behavior of the drug. The p...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199309148555
更新日期:1993-07-01 00:00:00
abstract::Chemotherapy has long been integral to the treatment of chronic lymphocytic leukemia (CLL). Fludarabine/cyclophosphamide, chlorambucil and bendamustine are commonly used as a backbone, depending on the patient's age and general health. The advent of the anti-CD20 monoclonal antibodies, such as rituximab and obinutuzum...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428194.2017.1330474
更新日期:2018-02-01 00:00:00
abstract::Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which r...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.3109/10428194.2010.543714
更新日期:2011-04-01 00:00:00
abstract::The role of tissue inhibitor of metalloproteinase-2 (TIMP-2) in extramedullary infiltration of acute leukemia is unclear. We demonstrated in our previous study that the up-regulation of TIMP-2 promoted SHI-1 cell invasion in vitro. We investigated in the present study whether TIMP-2 would have the same effect in vivo....
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2013.783214
更新日期:2013-12-01 00:00:00
abstract::The modern treatment of acute myelogenous leukemia (AML), consists of a polychemotherapeutic induction treatment followed by a post-remission therapy of variable intensity and duration and acute promyelocytic leukemia (APL) does not differ from this behavior. However, differently from the other AML subtypes, APL shows...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199309064259
更新日期:1993-01-01 00:00:00
abstract::Although current immunochemotherapy has increased the therapeutic efficacy in diffuse large B-cell lymphoma (DLBCL), there are still some patients who present unfavorable outcomes. Novel effective treatment strategies are needed to improve the prognosis of DLBCL. In this review, we discussed the functional mechanisms ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2019.1691194
更新日期:2020-04-01 00:00:00
abstract::B chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia (HCL) cells are refractory to many of the signals which activate normal B cells but are stimulated to proliferate by tumor necrosis factor (TNF). Cell signalling by TNF is mediated in part by the induction of the transcription factor families AP-1 and NF-k...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199509064938
更新日期:1995-06-01 00:00:00
abstract::We evaluated the association of two IL10 single nucleotide polymorphisms (SNPs) (rs1800896 and rs1800871) with non-Hodgkin lymphoma (NHL) risk in the three major races of the Malaysian population (Malay, Chinese and Indian; 317 cases and 330 controls). Our initial screening demonstrated that rs1800871 but not rs180089...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2014.907895
更新日期:2015-01-01 00:00:00
abstract::In order to identify the oncogene associated with malignant transformation 141 leukemia and malignant lymphoma patients were studied by FISH. Specific chromosome regions were translocated onto structurally abnormal chromosomes, resulting in partial tri-, tetra-, or pentasomy of these regions. We designated this type o...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199809050916
更新日期:1998-05-01 00:00:00
abstract::Speed of response to therapy predicts outcome in childhood lymphoblastic leukaemia. This observation has been made studying both blood and bone marrow in children on widely differing treatment regimens from the 1970s to the present day. It appears to be independent of other classical prognostic factors such as age and...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199809057609
更新日期:1998-11-01 00:00:00